Wet Age-Related Macular Degeneration (Wet AMD) Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2025-2035

Market Overview:

The wet age-related macular degeneration (Wet AMD) market reached a value of USD 9,528.8 Million across the top 7 markets (US, EU4, UK, and Japan) in 2024. Looking forward, IMARC Group expects the top 7 major markets to reach USD 18,317.5 Million by 2035, exhibiting a growth rate (CAGR) of 6.14% during 2025-2035.

The wet age-related macular degeneration (Wet AMD) market has been comprehensively analyzed in IMARC's new report titled "Wet Age-Related Macular Degeneration (Wet AMD) Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2025-2035". Wet Age-Related Macular Degeneration (Wet AMD) market is currently driven by factors such as a rising patient pool, improving diagnosis and drug treatment rates, an increase in the ageing population and improving efficacy of current and emerging therapies, etc. Wet Age-Related Macular Degeneration is an eye disease that destroys the macula, which is part of the retina at the back of the eye. Wet AMD involves the growth of abnormal blood vessels under the macula that leak blood and fluids into layers of the retina, including the macula. The symptoms of wet AMD usually start suddenly and are often severe. If a patient has wet AMD in one eye, it’s extremely likely that he will also get it in the other eye. With wet AMD, leaked blood and fluids can cause scar tissue to form and damage cells in the retina, damaging the central vision. Wet AMD can cause severe vision loss but does not lead to total blindness since a patient can retain his side vision. Having wet AMD can, however, make it extremely hard for people to do their daily things and can negatively impact the quality of their life.

Although the cause of Wet Age-Related Macular Degeneration is still largely unknown, age represents an important risk factor for developing Wet AMD. The disease is most common in people over 50 and becomes even more common in their 70s and 80s. Furthermore, smoking doubles the probability of developing wet AMD. In addition to cutting off oxygen to the eyes, researchers have found that smoking may damage cells and make it more difficult for nutrients to reach the eyes through the bloodstream. Other risk factors include gender, race, family history, heart disease, obesity etc.

IMARC Group's new report provides an exhaustive analysis of the Wet Age-Related Macular Degeneration market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for wet age-related macular degeneration and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the wet age-related macular degeneration market in any manner.

Time Period of the Study

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: 2025-2035

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the Wet Age-Related Macular Degeneration market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the Wet Age-Related Macular Degeneration market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current Wet Age-Related Macular Degeneration marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the Wet Age-Related Macular Degeneration market performed so far and how will it perform in the coming years?
  What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2035?
  What was the country-wise size of the Wet Age-Related Macular Degeneration across the seven major markets in 2024 and what will it look like in 2035?
  What is the growth rate of the Wet Age-Related Macular Degeneration across the seven major markets and what will be the expected growth over the next ten years?
  What are the key unmet needs in the market?

Epidemiology Insights

• What is the number of prevalent cases (​2019-2035​) of Wet Age-Related Macular Degeneration across the seven major markets?
• What is the number of prevalent cases (​2019-2035​) of Wet Age-Related Macular Degeneration by age across the seven major markets?
• What is the number of prevalent cases (​2019-2035​) of Wet Age-Related Macular Degeneration by gender across the seven major markets?
• What is the number of prevalent cases (​2019-2035​) of Wet Age-Related Macular Degeneration by type across the seven major markets?
• How many patients are diagnosed (​2019-2035​) with Wet Age-Related Macular Degeneration across the seven major markets?
• What is the size of the Wet Age-Related Macular Degeneration patient pool (​2019-2024​) across the seven major markets?
• What would be the forecasted patient pool (​2025-2035​) across the seven major markets?
• What are the key factors driving the epidemiological trend Wet Age-Related Macular Degeneration of?
• What will be the growth rate of patients across the seven major markets?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for Wet Age-Related Macular Degeneration drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Wet Age-Related Macular Degeneration market?
• What are the key regulatory events related to the Wet Age-Related Macular Degeneration market?
• What is the structure of clinical trial landscape by status related to the Wet Age-Related Macular Degeneration market?
• What is the structure of clinical trial landscape by phase related to the Wet Age-Related Macular Degeneration market?
• What is the structure of clinical trial landscape by route of administration related to the Wet Age-Related Macular Degeneration market?